Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Cappuzzo, Federico; Moro-Sibilot, Denis; Gautschi, Oliver; Boleti, Ekaterini; Felip, Enriqueta; Groen, Harry J.M.; Germonpré, Paul; Meldgaard, Peter; Arriola, Edurne; Steele, Nicola; Fox, Jesme; Schnell, Patrick; Engelsberg, Arne; Wolf, Jürgen
• Is Part Of: Lung cancer. Volume 87:Issue 2(2015:Feb.)
• Page Start: 89
• Page End: 95
• Publication Date: 2015-02
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.12.010
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Crizotinib is a standard of care for ALK-positive lung cancer.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Crizotinib-associated AEs are mostly mild to moderate in severity.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Appropriate monitoring and supportive therapies reduce the need for dosing modifications.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Patients may have prolonged benefit from crizotinib after disease progression.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Crizotinib should be continued for as long as the patient derives benefit.</p> </list-item> </list> </p> </sec> </abstract>